Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company and its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-4729 injections, and will conduct clinical trials in the near future.
智通财经·09/21/2026 08:57:04
语音播报
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company and its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received approval from the State Drug Administration to issue a “Drug Clinical Trial Approval Notice” for HRS-4729 injections, and will conduct clinical trials in the near future.